Anosmia Clinical Trial
Official title:
Validation of the Local Applicability of the 'TIB' Olfactory Test Device in the Era of COVID-19
Verified date | November 2021 |
Source | Taichung Veterans General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of this study was to evaluate the validity and test-retest reliability of the 'TIB' Olfactory Test Device, a new olfactory test tool developed by Top International Biotech, Taipei, and to determine its normative values. The olfactory function of 180 subjects was evaluated using both the traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC) and TIB. The subjects consisted of 60 healthy volunteers (normosmic group), 60 hyposmic patients, and 60 anosmic patients. The healthy volunteers were retested with the UPSIT-TC and TIB at an inter-test interval of at least 7 days. The cut-off scores of TIB among the different groups were determined by receiver operating characteristic curve.
Status | Completed |
Enrollment | 180 |
Est. completion date | September 16, 2021 |
Est. primary completion date | August 31, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 59 Years |
Eligibility | Inclusion Criteria: - Normosmic group were self-reported absence of deficits in olfaction. Hyposmic patients were loss of olfactory function with a phenyl ethyl alcohol (PEA) odor detection threshold below -1. Anosmic patients were loss of olfactory function with a PEA threshold equal to -1. Exclusion Criteria: - History of sinonasal symptoms within a week before the test |
Country | Name | City | State |
---|---|---|---|
Taiwan | Taichung Veterans General Hospital | Taichung |
Lead Sponsor | Collaborator |
---|---|
Taichung Veterans General Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | validity of TIB olfactory test | Criterion validity: Correlation between UPSIT-TC and TIB olfactory test | 30 minutes to 1 hour | |
Primary | Reliability of TIB olfactory test | Test-retest reliability | 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04964414 -
Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05445921 -
Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
|
Phase 1/Phase 2 | |
Completed |
NCT05812209 -
Stellate Ganglion Block to Treat Long COVID 19 Case Series
|
||
Withdrawn |
NCT02179554 -
Does Cardiopulmonary Bypass Change Olfaction?
|
||
Completed |
NCT04957563 -
Clinical Utility of Olfactory Rehabilitation: Treatment for Pacients With Neurosensorial Anosmia
|
N/A | |
Terminated |
NCT03680911 -
NAC for Head Trauma-induced Anosmia
|
Phase 3 | |
Completed |
NCT04657809 -
Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia
|
Phase 2 | |
Completed |
NCT04853836 -
Olfactory Disfunction and Co-ultraPEALut
|
Phase 4 | |
Recruiting |
NCT05040659 -
Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
|
||
Recruiting |
NCT05562050 -
Characteristics of the Anosmic Olfactory Mucosa
|
||
Recruiting |
NCT05384561 -
Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19
|
N/A | |
Enrolling by invitation |
NCT04764981 -
Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19)
|
N/A | |
Withdrawn |
NCT04408391 -
Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
|
||
Completed |
NCT04361474 -
Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity
|
Phase 3 | |
Completed |
NCT03990766 -
Smell Changes & Efficacy of Nasal Theophylline
|
Phase 2 | |
Completed |
NCT04797936 -
BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19
|
Phase 4 | |
Recruiting |
NCT04528329 -
Anosmia and / or Ageusia and Early Corticosteroid Use
|
Phase 4 | |
Completed |
NCT04789499 -
Smell in Covid-19 and Efficacy of Nasal Theophylline
|
Phase 2 | |
Recruiting |
NCT04384042 -
Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study
|
||
Completed |
NCT04390165 -
Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study
|